Comparative analysis of the efficacy of different treatments for idiopathic membranous nephropathy: a retrospectively real-world study

References

• Lai WL, Yeh TH, Chen PM, et al. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc. 2015;114(2):102–111.
   PubMed Web of Science ®Google Scholar
• Wu L, Lai J, Ling Y, et al. A review of the current practice of diagnosis and treatment of idiopathic membranous nephropathy in China. Med Sci Monit. 2021;27:e930097.
   PubMed Web of Science ®Google Scholar
• Hu SL, Wang D, Gou WJ, et al. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J Nephrol. 2014;27(2):111–116.
   PubMed Web of Science ®Google Scholar
• Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287.
   PubMed Web of Science ®Google Scholar
• Xie J, Chen N. Primary glomerulonephritis in mainland China: an overview. Contrib Nephrol. 2013;181:1–11.
   PubMed Web of Science ®Google Scholar
• Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol. 1997;8(4):664–674.
   PubMed Web of Science ®Google Scholar
• Yang LY, Wu YS, Dai BB, et al. sPLA2-IB level correlates with hyperlipidemia and the prognosis of idiopathic membranous nephropathy. Curr Med Sci. 2020;40(4):683–690.
   PubMed Web of Science ®Google Scholar
• Li J, Chen B, Gao C, et al. Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis. BMC Nephrol. 2019;20(1):467.
   PubMed Web of Science ®Google Scholar
• Zuo K, Wu Y, Li SJ, et al. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445–453.
   PubMed Web of Science ®Google Scholar
• Huh H, Lee H, Lee JP, et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. BMC Nephrol. 2017;18(1):104.
   PubMedGoogle Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:186–197.
   Web of Science ®Google Scholar
• Li C, Li P, Guo W, et al. The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study. Korean J Intern Med. 2022;37(1):154–166.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu Q, Liao Y, et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. Am J Med Sci. 2013;345(2):81–87.
   PubMed Web of Science ®Google Scholar
• Praga M, Barrio V, Juárez GF, et al. Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924–930.
   PubMed Web of Science ®Google Scholar
• Wang X, Cui Z, Zhang YM, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrol Dial Transplant. 2018;33(9):1558–1563.
   PubMed Web of Science ®Google Scholar
• Teisseyre M, Cremoni M, Boyer-Suavet S, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy. Front Immunol. 2022;13:859419.
   PubMed Web of Science ®Google Scholar
• Zou H, Jiang F, Xu G. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. Intern Med J. 2020;50(5):612–619.
   PubMed Web of Science ®Google Scholar
• Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998;31(1):1–11.
   PubMed Web of Science ®Google Scholar
• Abe S, Amagasaki Y, Konishi K, et al. Idiopathic membranous glomerulonephritis: aspects of geographical differences. J Clin Pathol. 1986;39(11):1193–1198.
   PubMed Web of Science ®Google Scholar
• Wehrmann M, Bohle A, Bogenschütz O, et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol. 1989;31(2):67–76.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310(15):946–950.
   PubMed Web of Science ®Google Scholar
• Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int. 1992;41(2):428–434.
   PubMed Web of Science ®Google Scholar
• Dumoulin A, Hill GS, Montseny JJ, et al. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41(1):38–48.
   PubMed Web of Science ®Google Scholar
• Gupta R, Sharma A, Mahanta PJ, et al. Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinico-pathological and stereological study. Nephrol Dial Transplant. 2010;25(2):444–449.
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang Y, Gao C, et al. Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody. PeerJ. 2020;8:e8650.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults. Int J Nephrol Renovasc Dis. 2018;11:241–247.
   PubMed Web of Science ®Google Scholar
• Deng L, Huang Q, Wang J, et al. Efficacy and safety of different immunosuppressive therapies in patients with membranous nephropathy and high PLA2R antibody titer. Front Pharmacol. 2021;12:786334.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545–2558.
   PubMed Web of Science ®Google Scholar
• Chi JN, Lai TS, Wu CF, et al. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy. J Formos Med Assoc. 2019;118(5):898–906.
   PubMed Web of Science ®Google Scholar
• Zhang MF, Huang J, Zhang YM, et al. Complement activation products in the circulation and urine of primary membranous nephropathy. BMC Nephrol. 2019;20(1):313.
   PubMed Web of Science ®Google Scholar